SoloSmart, a single-piece, add-on connected device works with Sanofi’s SoloStar and DoubleStar insulin injection pens. It records the insulin dose, date and time of injection. Through this partnership, the company’s can offer data visualization through the Glooko app. Patients can share data with healthcare professionals for connected care in their diabetes management.
Get the full story at our sister site, Drug Delivery Business News.
Glooko announced today that it received ISO 27001 certification for its data management and remote patient monitoring platforms.
Palo Alto, California-based Glooko develops remote patient monitoring and chronic care management products. These include data management technologies for insulin delivery devices.
ISO 27001, an international compliance framework, serves as the international security standard for protecting customer information.
Get the full story at our sister site, Drug Delivery Business News.
Diabetes management technology developer Glooko announced today that it appointed Alfonso “Chito” Zulueta to its board of directors.
Zulueta joins Palo Alto, California-based Glooko’s board having spent more than 30 years with Eli Lilly and Company, serving as a senior executive across an array of global business and commercial units.
Get the full story at our sister site, Drug Delivery Business News.
In the new technology integration, users with diabetes will be able to transfer recorded data from the Terumo Medisafe With insulin patch pump into the Glooko management platform, allowing for the visualization of insulin dosage, food and activities in graphs.
Get the full story at our sister site, Drug Delivery Business News.
Paris-based Diabnext’s mobile app tracks diabetes data so that physicians can collaborate with their patients to monitor individual patient data and provide remote care. Financial details of the acquisition were not disclosed.
Get the full story at our sister site, Drug Delivery Business News.
Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with on Lilly’s latest insulin pen.
The Tempo Pen is a modified version of Lilly’s existing prefilled, disposable insulin pen to which the Tempo Smart Button — in late-stage development – attaches. Through these new agreements, the Tempo Smart Button will pair with software and/or medical devices offered by Dexcom (NSDQ:DXCM), Glooko, myDiabby Healthcare (Bordeaux, France) and Roche, with its mySugr app, to facilitate the integration of personalized data and actionable insights.
Get the full story on our sister site, Drug Delivery Business News.
Diabetes and obesity management tech developer Glooko announced today that it raised $30 million in a Series D financing round.
Palo Alto, Calif.-based Glooko, which develops remote patient monitoring and chronic care management products including data management technologies for insulin delivery devices, said in a news release that proceeds from the financing will be used to accelerate organic growth and strategic initiatives across its product line.
Get the full story at our sister site, Drug Delivery Business News.